Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

122.56 +4.41 (+3.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,280,572
Open 118.61
Bid (Size) 122.50 (100)
Ask (Size) 122.88 (100)
Prev. Close 118.15
Today's Range 118.58 - 122.75
52wk Range 86.08 - 124.61
Shares Outstanding 1,253,809,440
Dividend Yield 2.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is the AI Rally a Bubble? Impact on Commodity Demand and Defensive Stock Rotation
As November 2025 unfolds, a subtle yet significant shift in market sentiment is becoming increasingly palpable among financial analysts and retail investors alike. What was once an almost universally... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government

Performance

YTD
+33.4%
+33.4%
1 Month
+3.7%
+3.7%
3 Month
+1.7%
+1.7%
6 Month
+18.1%
+18.1%
1 Year
+26.3%
+26.3%

More News

Read More
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown
Via Stocktwits
GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals
Via 24-7 Press Release
What's going on in today's session: S&P500 movers
Via Chartmill
Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend
Via Benzinga
Gilead Provides Update on Phase 3 ASCENT-07 Study
From Gilead Sciences, Inc.
Via Business Wire
Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
3 Cash-Rich Stocks With High Growth Potential Right Now
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock
Via Chartmill
Moderna Earnings: What To Look For From MRNA
Via StockStory
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Inc (NASDAQ:GILD): A Dividend Stock with a Secure Payout and Strong Fundamentals
Via Chartmill
Amgen Earnings: What To Look For From AMGN
Via StockStory
Topics Artificial Intelligence
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
Via StockStory
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect
Via StockStory
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Via MarketMinute
Topics Intellectual Property
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Via Benzinga
Topics Earnings
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 122.56
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 11/11/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 153.67B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 154B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.